Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 119791

Sort by

Sort Order Select

Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2024-212973

Published: 2024

Journal Articles

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Blood (2024) 144 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2024-212970

Published: 2024

Journal Articles

Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis

Laurent Martin, Darko Maric, Salam Idriss, Marine Delamare, Amandine Le Roy, Nada Maaziz, Amandine Caillaud, Karim Si-Tayeb, Florence Robriquet, Marion Lenglet, Lucie Erceau, Christine Bellanné-Chantelot, Isabelle Plo, Bernard Aral, Céline Garrec, Fabrice Airaud, Clara Gianfermi, Vincent Antunes, Anna Keppner, Sarah Mathilda Vincent, Alexis Desfontaine, Nina Modé, Fabien Laporte, Anne Gaignerie, Caroline Chariau, Isabelle Leray, Coline Rogue, Laurent David, Richard Redon, Stephane Bezieau, Lamisse Mansour, Frederic Galacteros, Thibault Maillet, Marlène Pasquet, Pierre Cougoul, Anne-Marie Nloga, Claude Gardin, Corinne Guitton, Viviane Dubruille, Vannina Giacobbi-Milet, Thierry Leblanc, Zuhre Kaya, Denis Semama, Chloe James, Serge Carillo, Marlène Ochmann, Anders Waage, Erwan Mortier, Mike Maillasson, Agnès Quéméner, Holger Cario, Radek C. Skoda, Yaël Zermati, David Hoogewijs, Alexandre Marchand, Francois Girodon, Betty Gardie

Blood (2024) 144 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2024-213000

Published: 2024

Journal Articles

Extended Treatment of Venous Thromboembolism with Reduced- Vs Full-Dose Direct Oral Anticoagulants in Patients at High Risk of Recurrence

Francis Couturaud, Olivier Sanchez, Nicolas Meneveau, Laurent Bertoletti, Gilles Pernod, Isabelle Mahe, Emilie Presles, Philippe Girard, Cécile Tromeur, Patrick Mismetti, Silvy Laporte, Christophe Leroyer

Blood (2024) 144 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2024-212912

Published: 2024

Journal Articles

Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Jihyun Song, Soo Jin Kim, Josef T. Prchal

Blood (2024) 144 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2024-213103

Published: 2024

Journal Articles

Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities

Blood (2024) 144 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2024-212967

Published: 2024

Journal Articles

Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States

Andrew T. Kuykendall, Francesca Palandri, Shiyuan Zhang, Tom Liu, Mirko Fillbrunn, Adina Zhang, Gautam Sajeev, James Signorovitch, Dwaipayan Patnaik, Aaron T. Gerds

Blood (2024) 144 (Supplement 1): 3804.

https://doi.org/10.1182/blood-2024-205380

Published: 2024

Journal Articles

Clinical Significance of Mutant TP53 Alleles and Functions in Acute Myeloid Leukemia: HM-Screen-Japan 01/02 Study

Kensuke Kojima, Fumiya Ogasawara, Sunggi Chi, Kentaro Fukushima, Yosuke Minami, Tomoaki Ueda

Blood (2024) 144 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2024-194167

Published: 2024

Journal Articles

Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 ‘Midotarg Pilot‘

Joanna Canham, Ian Thomas, Nigel H. Russell, Jane Leahy, Abin Thomas, Steve Knapper, Lucy Marsh, Huda Mohamed, Sean Johnson

Blood (2024) 144 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2024-205133

Published: 2024

Journal Articles

Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)

Cassandra Duarte, Diana Abbott, Christine M. McMahon, Andrew Kent, Marc Schwartz, Jonathan Gutman, Daniel A Pollyea, Maria L Amaya

Blood (2024) 144 (Supplement 1): 3803.

https://doi.org/10.1182/blood-2024-201061

Published: 2024

Journal Articles

FLAG IDA Venetoclax in Newly Diagnosed Pediatric and AYA Patients with AML

Reeja Raj, Samanta Catueno, Amber Gibson, David McCall, Miriam B. Garcia, Cesar Nunez, Michael E. Roth, Koji Sasaki, Priti Tewari, Branko Cuglievan, Courtney D. DiNardo

Blood (2024) 144 (Supplement 1): 2906.

https://doi.org/10.1182/blood-2024-211771

Published: 2024

Journal Articles

Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis

John X Wei, Mendel Goldfinger, Marina Konopleva, Ioannis Mantzaris, Amit Verma, Eric J. Feldman

Blood (2024) 144 (Supplement 1): 3802.

https://doi.org/10.1182/blood-2024-206488

Published: 2024

Journal Articles

Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission

Blood (2024) 144 (Supplement 1): 2905.

https://doi.org/10.1182/blood-2024-209998

Published: 2024

Journal Articles

Extended Vs Standard Hypomethylating Agent Dosing in Combination with Venetoclax in Newly Diagnosed Acute Myeloid Leukemia

Georgio Medawar, Serena Tharakan, Dahniel L Sastow, Vincent Lok, Su Bin Hahn, Preston Perez, Abigail Demers, David M Swoboda, Douglas Tremblay, Alexander Coltoff

Blood (2024) 144 (Supplement 1): 2904.

https://doi.org/10.1182/blood-2024-209414

Published: 2024

Journal Articles

Molecular Features of Acute Myeloid Leukemia in Hispanics: An Analysis from the Marrow Consortium

Blood (2024) 144 (Supplement 1): 3801.

https://doi.org/10.1182/blood-2024-212140

Published: 2024

Journal Articles

Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2024) 144 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2024-207962

Published: 2024

Journal Articles

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Blood (2024) 144 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2024-210768

Published: 2024

Journal Articles

Venetoclax, Azacitidine, Combined with Low-Dose Cytarabine in Older Newly Diagnosed Acute Myeloid Leukemia：the Result of a Prospective, Multicenter, Open, Randomized Controlled Trials

Blood (2024) 144 (Supplement 1): 2902.

https://doi.org/10.1182/blood-2024-206513

Published: 2024

Journal Articles

Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry

Blood (2024) 144 (Supplement 1): 3799.

https://doi.org/10.1182/blood-2024-209389

Published: 2024

Journal Articles

A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia

Hannah Goulart, Hagop M. Kantarjian, Naval Daver, Musa Yilmaz, Guillermo Garcia-Manero, Kelly S. Chien, Jan A. Burger, Naveen Pemmaraju, Courtney D. DiNardo, Nicholas J. Short, Guillermo Montalban-Bravo, Abhishek Maiti, Danielle Hammond, Ghayas C. Issa, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 2901.

https://doi.org/10.1182/blood-2024-205340

Published: 2024

NARROW

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis

Extended Treatment of Venous Thromboembolism with Reduced- Vs Full-Dose Direct Oral Anticoagulants in Patients at High Risk of Recurrence

Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities

Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States

Clinical Significance of Mutant TP53 Alleles and Functions in Acute Myeloid Leukemia: HM-Screen-Japan 01/02 Study

Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 ‘Midotarg Pilot‘

Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)

FLAG IDA Venetoclax in Newly Diagnosed Pediatric and AYA Patients with AML

Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis

Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission

Extended Vs Standard Hypomethylating Agent Dosing in Combination with Venetoclax in Newly Diagnosed Acute Myeloid Leukemia

Molecular Features of Acute Myeloid Leukemia in Hispanics: An Analysis from the Marrow Consortium

Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Venetoclax, Azacitidine, Combined with Low-Dose Cytarabine in Older Newly Diagnosed Acute Myeloid Leukemia：the Result of a Prospective, Multicenter, Open, Randomized Controlled Trials

A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only